HERVolution Therapeutics

HERVolution Therapeutics is a biotechnology company focused on the 'dark genome,' specifically targeting Human Endogenous Retroviruses (HERVs). These genetic remnants of ancient viral infections comprise 8% of the human genome and are typically dormant but reactivate during aging and disease, contributing to cancer, metabolic disorders, and neurodegeneration. The company utilizes a proprietary engineering platform to redesign HERV antigens, making them visible to the immune system and breaking 'self-tolerance.' Their approach combines adenoviral vectors, virus-like particles (VLPs), and mRNA modalities to induce potent T and B cell responses against previously undruggable targets in oncology and longevity.